Antibodies to Streptococcus pneumoniae 6B capsular polysaccharide (PS) induced with a 23-valent PS vaccine among 25 adults were examined. The magnitude of antibody responses among different subjects was highly correlated with the amount of anti-6B antibodies expressing IgG (r = 0.98) and A (r = 0.93) isotypes. Most individuals produced one or two dominant IgG antibody clones as identified by their isoelectric points. Two antibody clones with unique amino acid sequences could be readily purified, and the sequences of their light chains match those of AlIA17 VIC and hslv2046 VA genes. Anti-6B antibodies isolated from different subjects used various VL genes and differed in their cross-reactivity with 6A PS. An isoelectric focusing study suggests that some IgG antibodies induced with 6B PS bind 6A PS with lower avidity.
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Streptococcus pneumoniae is a significant pathogen for young children and old adults. It accounts for a large fraction of otitis media and bacterial pneumonia cases [1] . It is also a leading cause of bacterial meningitis and sepsis [1] . Eightyfour serotypes ofS. pneumoniae are recognized by their distinct polysaccharide (PS) capsules, although some PS capsules (e.g., 6A and 6B) are structurally very similar [2] . Among 84 serotypes, 7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) account for~80% of isolates from invasive infections by S. pneumoniae in children [3, 4] .
There is a need for effective vaccines against S. pneumoniae because the prevalence of antibiotic-resistant S. pneumoniae is high [5] and because sepsis is associated with very high rates of mortality, even with the appropriate antibiotic treatment [1] . Almost all vaccines are designed to induce antibodies to the capsular PS of S. pneumoniae, which are known to be protective. The current PS vaccine containing capsular PS from 23 commonly pathogenic serotypes is effective only in select adult populations. To produce vaccines effective in young children, new vaccines containing PS-protein conjugates containing several (e.g., the 7 listed above) serotypes are being developed [3] .
Among the antibodies to the capsular PS of S. pneumoniae induced by the vaccines, antibodies to the capsular PS of 6B serotype (hereafter referred to as 6B PS) may require study more than antibodies to other serotypes. First, although several studies have examined correlation [6] [7] [8] , a recent study using standardized ELISA and opsonic assays found a weak (r = .51) correlation between anti-6B antibody concentration and its opsonization capacity [8] . Second, the functional variability in anti -6B PS antibodies may be clinically significant, since 6B is poorly immunogenic [1] and antibodies to 6B would be present in limited amounts in children. Third, antibodies made with 6B are generally cross-reactive with 6A PS and are assumed, in formulating vaccines, to be cross-protective against S. pneumoniae 6A, another commonly pathogenic serotype. However, no clear evidence for cross-protection in humans is yet available [9] . Last, there are questions about specificities of some assays for anti-capsular PS antibodies [l O, 11], and more knowledge about the antibody structure would facilitate improvement of the assays. Therefore, we have investigated the antibody repertoire available in the adult population by examining the structure of anti -6B PS antibodies and their ability to bind closely related antigens.
Materials and Methods
Anti-pneumococcal antisera. Twenty-five healthy adult volunteers were immunized with polyvalent pneumococcal vaccine (PNU-IMMUNE 23, lot 372-977, 390-966; Lederle Laboratories, Pearl River, NY), and serum samples were collected at the time of immunization and 1 month later. A serum pool (89-SF), used as the standard in all assays, was obtained for this study from C. Frasch (Food and Drug Administration, Bethesda, MD). The standard was assumed to contain 24.3, 16.9, 3, and 1.5 I-lg/mL of total, IgG, IgM, and IgA anti -6B PS antibody, respectively (Frasch C, personal communication).
Reagents. Crude C-polysaccharide (C-PS) used for absorption was obtained either from P. Anderson (University of Rochester, Rochester, NY) or from Statens Seruminstitut (Copenhagen). The type 6A and 6B pneumococcal capsular PSs were purchased from American Type Culture Collection (Rockville, MD). The anti-nn 1996; 174 (July) IgG2 monoclonal antibodies HP6016 and GOM-I have been described [12] , as have the anti-K (HK2) and anti-A (HL 1) monoclonal antibodies [13] . Another anti-A monoclonal (HP6056) [12] and anti-K (HP6156) were provided by G. Carlone (CDC, Atlanta). An anti-IgM antibody (HB57) was from the American Type Culture Collection [14] . Alkaline phosphatase-conjugated polyclonal antisera (goat anti-human immunoglobulins) were purchased from Sigma (St. Louis). OAK-I, KBI3, and Bl2 are monoclonal antibodies specific for human VKIa, VKII, and VKIll subgroups, respectively, as described [15, 16] .
ELISA. The amount of anti-serotype 6B antibody expressing a specific VK subgroup or isotype was determined by sandwichtype immunoassays as described [IO, 11, 15] . Briefly, wells of Immulon II plates (Dynatech, Chantilly, VA) were coated at 37°C with 10 ,ug/mL 6B PS overnight in PBS, which was prepared fresh using water from a water purification system (Milli-Q UF; Millipore, Bedford, MA) to minimize the background signal. The plates were washed and blocked with PBS containing 1% nonfat milk (Carnation, Los Angeles). The human serum pool 89-SF was used as a standard. Samples were preabsorbed with 3 /l,g of C-PS per 20 ,uL of serum in a total volume of 1 mL of diluent for 30 min at room temperature. The serum samples were then added to wells, titrated, and incubated for 3-5 h at room temperature. Plates were subsequently washed, followed by addition of alkaline phosphatase-conjugated goat antibody against human immunoglobulin isotypes. In some cases, one of the above-mentioned anti -human immunoglobulin monoclonal antibodies was added to wells, and goat anti-mouse immunoglobulin antibody labeled with alkaline phosphatase was added later. The amount of the enzyme immobilized to the well was determined with p-nitrophenyl phosphate substrate (Sigma) in diethanolamine buffer. Optical density at 405 nm was read with a microplate reader (Cambridge Technology, Watertown, MA). The amount of antibody in the sample was determined by comparing the optical density of the samples to that of the standard using piecewise linear interpolation.
Affinity chromatography. To remove immunoglobulins expressing IgG2, K and A isotypes, serum samples were passed over columns of Sepharose 4B conjugated with either HP6016, HK2, or HL 1 [17] . The removal was monitored by measuring the concentration of IgG2, K, and A isotypes on samples obtained before and after absorption using ELISA as described above with GOM-I (for IgG2), HP6156 (for K), and HP6054 (for A) detection. To monitor the extent of the sample dilution during the procedure, the levels of anti-6B antibodies using IgM, K, or A isotypes were also measured by ELISA using HB57 (for IgM), HK2 (for K), and HP6054 (for A).
Isoelectric focusing (IEF) method. IEF was done in an agarose gel essentially as described [17] . The gel contained 1% IsoGel agarose (FMC, Rockland, ME),I 0% sorbitol, and 4.3% (vol/vol) pH 8-10.5 and 0.3% (vol/vol) pH 5-8 ampholytes (LKB; purchased from Sigma). Anti-6A or -6B antibodies were visualized using 125I-conjugated 6A or 6B PS, which were prepared as described [18] from tyramine-conjugated PS. In some IEF gels, the effect of anti -C-PS was examined by absorbing 10 ,uL of sera with 1.5 ,ug of C-PS and by exposing the gel to 125I-labeled 6B in the presence of 3 ,ug/mL C-PS.
Purification ofanti-6B antibody from immune serum and determination of its amino acid sequence. Purification was done as described for antibodies to Haemophilus influenzae type b (Hib) PS [19] with slight modifications as described below. The immunoglobulin fraction was separated from the immune serum by precipitating the immunoglobulin in 50% saturated ammonium sulfate. The immunoglobulin fraction was passed over a Sepharose column conjugated with 6B PS. The 6B was conjugated to Sepharose as described [19] . The 6B-Sepharose column saturated with anti-6B antibody was washed first with 100 mM NaCl containing 50 mM TRIS (pH 7.4), next with 100 mM borate buffer (pH 8.4) containing 5 mM phosphocholine and 0.01 % Tween 20, and last with 150 mM NaCl. Preliminary studies showed that 5 mM phosphocholine eluted most anti-C-PS antibodies, which bind haptenic determinant phosphocholine [20] . Anti-6B antibody was eluted from the column with 3.5 M MgCb, pH 3.5, and the elution fraction containing purified protein was neutralized with 1 M TRIS and dialyzed against normal saline buffered with 50 mM TRIS (pH 7.5). To obtain the IgG fraction, the antibody was passed over Sepharose columns coupled with HB57 and HAl, monoclonal antibodies specific for IgM and IgA, respectively. The purified antibody was assessed for its antigen specificity for 6B, purity, and clonality by using ELISA and IEF methods as described above. The L chains of this antibody were separated from the H chain in an SDS-PAGE gel and its N-terminal amino acid sequence was determined using a gas-phase sequencer as described [19] . Unlike K light chain, A light chain was found to be blocked at the N-terminus, and the A chain was digested with CNBr to cleave the chain at methionine before the amino acid sequence was obtained [19] .
Results
Heavy and light chain isotypes ofantibodies against S. pneumoniae type 6B. Serum samples were obtained from 25 adults before and 1 month after vaccination, and their anti-6B antibody levels were determined using 89-SF as the standard (table  1) . In the preimmune sera, the majority of antibodies were IgM. Vaccination increased the total antibody levels by~5 fold, comparable to a previously reported study [6] . The increase was significant for all three isotypes (P < .025, twotailed t test). The response was significantly higher for IgG (2 I-fold increase) than for IgA (5.2-fold increase) or IgM (1.9-fold increase) isotypes. IgG antibodies accounted for the majority of total anti-6B antibodies in the postimmune sera. Also, the magnitude ofIgG anti-6B antibody response was correlated with the magnitude of total antibody response ( figure 1, left) . Most of the IgG anti-6B antibodies were further restricted to IgG2 isotype, inasmuch as the removal of IgG2 from 5 randomly chosen serum samples and 89-SF reduced~90% (range, 84%-98%) of anti-6B PS antibodies but very little « 10%) irrelevant antibodies.
The amounts of anti-6B made up of the A and K chains were then determined in the standard (89-SF). When immunoglobulins expressing either K or A chains were depleted from 89-SF by affinity chromatography, 72.4% and 27.6%, respectively, of anti-6B antibodies remained. Since 89-SF contains 24.3 ,ugl mL anti-6B antibody, we assigned 17.6 ,ug/mL of K and 6.7 ,ug/mL of A as the concentration of anti-6B light chains in 89-SF. The samples from the 25 adults were then studied using 89-SF as the standard. The study showed that the response is higher in A. than in K (I l-fold vs. 4-fold increase, P = .011, two-tailed t test). Ofnote, high responders to the vaccine preferentially elicited anti-6B antibodies using A. chain. As seen in figure 1 (right), the 7 highest responders produced more A. than K anti-6B. In contrast, only 1 of the 6 lowest responders produced more A. than K antibody. Also, there was a striking correlation between the A. anti-6B antibody levels and the total anti-6B antibody concentration (r = .93), but the r value between anti-6B and K anti-6B was only 004. Although VK genes were originally divided into subgroups based on amino acid sequence homology, their subgroups can be rapidly identified with antibodies [15, 16] . To test ifanti-6B antibodies can be formed with multiple VL genes, we selected several serum samples expressing high levels of anti-6B antibodies with the K chain and studied their V K subgroups serologically. As shown in figure 2 , sample A expressed a high level of antibodies using VKI and a low level of V KII antibodies. In contrast, sample B expressed a high level of VKII but a low level of V KI. Although these assays do not provide absolute antibody concentrations, the data support the possibility that multiple V K genes can be used to form antibodies for 6B PS.
Only a few clones of IgG antibodies to S. pneumoniae type 6B PS are expressed in a given person. To assess the number Expression of anti-6B antibodies using YK genes in 3 YK subgroups among 3 subjects. Reference serum pool (89-SF) was assumed to contain 100 U/mL for each subgroup. Subjects were selected from 25 in our study for their differential expression of YK subgroups in anti-6B antibodies.
are not clear. For instance, samples P18B and P23B (figure 4, lanes 8 and 9) show staining of a region in the left panel with unclear findings. Further studies of sample P23B show that it probably contains two fgG antibody clones (figure 4B). IgM and IgA antibodies do not clearl y focus into discrete bands in these gels , and the staining region (e.g., figure 3 , lane I) in the top of the gels likely represents antibodies of these isotypes . Despite these caveats, mo st samples contain only few (one to three) dominant clones of IgG anti-6B antibody.
The 125 1 label is contaminated with C-PS [22, 23] , and some of these bands might repre sent bind ing to C-PS or other contaminants. To evaluate the effect of anti -C-PS antibody in our estimates of the number of anti-6B antibody clones, we examined 9 postimmune serum samples before or after absorption with C-PS (figure 3). Sample 3B (lanes 3 in both panels) was chosen because it contained a large amount of anti-C-PS (44 f-Lg/mL) and little anti-capsular antibody (~4 f-Lg/mL). Sample 3B showed only faint staining bands before or after the absorption. With the other samples, absorption caused no alteration in the number of visible bands (figure 3B). TEPC 15, an anti-C-PS myeloma protein, at I ng/lane, could not be detected with our 6B label in IEF, although 0.01 ng of anti-6B per lane was detectable (data not shown). Thus, most (if not all) of the bands seen in our IEF were antibodies to the capsular PS.
Clonal antibodies with unique am ino acid sequences can be purified. fEF studies strongly suggested that antibody responses to 6B PS arc limited to on e or few clones, similar to what has been observed for anti-Bib antibodies [19. 24] . To furth er demonstrate the oligoclonality of anti -6B PS antibod ies. we purified two IgG antibody clones from 2 immune sera (PI6C and P9C) containing a relatively large amount of IgG antibodies (~30 f-Lg /mL) using a set of affinity chromatography steps, as we have previously described for anti-Hib antib odies [19] . We then determined the amino acid sequence(s) of the L chains of the purified antibodies ( figure  5 ). When we compared our sequence to the sequences of all 40 functional VK genes [25] , the 16 residues ofPI6C matched exactly the predicted sequence of YK genes named Al and A17, which differ by one amino acid at residue 54 [25] . In addition to Al and A17, two VK genes (A3 and A19) had sequences most similar to our sequence, but A3 and A 19 sequences differed from our sequence by two residues. When the internal sequence obtained from P9C was studied, its sequence matched the translated sequence of a yx. gene hslv2046 [26] . The fact that we can readily purify clonal antibodies with unique amino acid sequences supports the conclusion that anti-6B antibody response in a given person is limited to one or few clones.
Anti-6B PS antibody clones are cross-reactive with 6A PS to varying degrees.
It is well known that immunization with 6B PS induces antibodies binding 6A PS. This cross-reaction may arise due to either the production of anti-6B antibodies cross-reacting with 6A PS or the production of additional antibodies binding only 6A PS. To distinguish these possibilities, we examined individual antibody clones of anti-6B antibodies for binding 6A PS by separating them in an IEF gel and overlaying the IEF gel with 6B PS (18 million cpm/ug of PS) (figure 4B) as well as 6A PS (25 million cpml,ug ofPS) (figure 4A) labels . All anti-6B antibody clones were found to be crossreactive with 6A. Although the amount of antisera loaded in each lane was adjusted to give similar staining intensities with 6B label, the staining intensities of the bands with 6A were variable. For instance, the antibody clone in PI7B binds 6B label intensely (4B, lane 7) but binds 6A label only weakly (4A lane 7). This finding suggests that vaccination with 6B PS stimulates anti-6B antibody clones that cross-react with 6A PS to varying degrees .
19G antibodies vary in their antigen binding specificities. To assess the cross-reactivity of the (oligo)clonal IgG anti-6B antibodies quantitatively, we studied their ability to bind 6B PS immobilized on the plastic surface, in the presence of other PS such as 6B PS, 6A PS, or Hib PS . Hib PS is a linear polymer of ribitol phosphates like 6A or 6B PS, and Hib PS (up to 100 p,g/rnL) did not inhibit the binding of anti-6B antibodies (data not shown). When 6A and 6B PS were used as inhibitors, several patterns of inhibition were found . To obtain an overall view of the cross-reaction by all the samples, the concentrations of 6A or 6B PS needed for 50% inhibition are shown in figure 6 . In 12 samples, inhibition by 6A PS was 3-to IOO-fold less efficient than that by 6B PS . In 6 samples, the difference was > 1OO-fold. With I sample, it was found reproducibly that neither 6A nor 6B was able to inhibit the binding at 50 p,glmL. The antibody may recognize an epitope that appears only in the PS immobilized to plastic. These studies clearly show that anti-6B antibodies arc variable in their cross-reaction with 6A PS .
Ai /A17 sequence P16C L chain A3 /A19 sequence JID 1996; 174 (July) Discussion 100.0 -, -------------------that genetic [32] or vaccine-(or antigen-) [33] related factors could influence the selection of the dominant antibody clones. In humans, Km allotypes were found to affect the expression of antibodies using VK genes [15, 34] . Since the magnitude of antibody response to 68 PS is found strongly associated with the expression of VA gene(s), host factors (such as genes linked to CA alleles) may influence the VA usage and the magnitude of antibody response to 68. Study of factors influencing anti-68 antibody should also be interesting because humans uniquely have 7 (or lOin some persons [35] ) CA genes per haploid genome, and very little is known about the factors regulating the expression of VA and CA genes.
Genetic and vaccine-related factors do not provide complete explanations for the dominant expression of one single clone in a given person. For instance, one preparation of a vaccine could induce the expression of different clones of antibodies to PS antigens among inbred mice [36] or among monozygotic twins [30] . It is also shown that prior exposure to an antigen can influence the antibody repertoire in a subsequent exposure to distinct but similar antigens [37, 38] . Thus, one possible explanation for the individual selection of a particular clone is immune memory to related antigens. Conjugate vaccines induce immune memory, and immunization with 68 PS-protein conjugate vaccine may influence the antibody repertoire to 6A PS antigen.
Sera from most persons have antibodies to C-PS [39] [40] [41] , which unavoidably contaminate capsular PS [22] . Anti-C-PS antibodies can be detected as anti-capsular antibodies (i.e., anti-68) and can complicate the studies of antibodies to capsular PS [10, 42] . We have reported that the effect of contaminating anti -C-PS on the assay results is highly dependent on assay methods [18] . The number of antibody bands seen in our IEF gels did not change much with the removal of anti-C-PS, in contrast to the findings by Konradsen et a1. [30] , who used a slightly different IEF method and found their IEF results were clearly affected by anti-C-PS. This difference further emphasizes that the effect of anti -C-PS on assay results is dependent on the assay method.
Multiple factors influence the functional potency of antibodies. Anti-C-PS are not as protective as anti-capsule antibodies [41, [43] [44] [45] , perhaps because the C-PS is located too deeply on the bacterial surface for neutrophils to recognize [41] . In some cases, antibodies may not be so protective because they bind the epitopes expressed only sparsely on bacteria [46] or bind them with low avidities [47, 48] . Thus, not all anti-68 antibodies are likely to be equally protective. Given that an individual has only one or two dominant antibody clones selected from a large library of antibody clones, persons vaccinated with 68 PS should produce antisera varying in their protective potency against 68. Furthermore, anti-68 antibodies appear to be variable in their cross-reactivity with 6A PS, and immunization with 68 PS could induce antibodies with variable cross-protective potencies against S. pneumoniae 6A. It should be determined whether cross-reactive antibodies are cross-pro- . Concentrations of6B (v axis) and 6A (x axis) polysaccharide (PS) required to inhibit half of antibody bound to ELISA wells for each individual sample. Solid line indicates that 6A and 6B are equally potent in inhibition, and dashed line indicates that 6A PS is I DO-fold less potent than 6B PS. All sera were diluted 400-fold.
Many studies reported that individual antibody response to a PS antigen is often highly restricted [19, 24, [27] [28] [29] [30] . For instance, a mouse produces only one or two dominant IgG antibody clones to group A carbohydrate of Streptococcus pyogenes even after a course of multiple immunizations [28] .lndividual humans produce a similar number of IgG antibody clones against group A carbohydrate of S. pyogenes [29] or to the capsular PS of S. pneumoniae serotype 1 [30] . In the case of antibodies to Hib, we have shown that antibodies are so oligoclonal that individual anti-Hib antibody clones with unique amino acid sequences can be purified [19] . Here, we extend these observations to IgG anti-68 antibodies. Individual subjects have discrete anti-68 antibody bands in an IEF gel as they do anti-Hib antibodies. Also, from 2 immune sera we could readily purify clonal antibodies to 68 with unique amino acid sequences.
When anti-68 antibodies from different persons are examined, several lines of evidence indicate that those anti-6B antibodies use heterogenous V regions. First, anti-68 antibodies can use V K as well as VA genes, and serologic studies suggest that several genes belonging to different VK subgroups are used. Second, IgG anti-6B antibodies display variable isoelectric points. Since IgG anti-6B antibodies are often of IgG2 A isotypes, the variabilities in IEF pattern suggests variabilities in the V regions. Last, the antibodies using VA genes also showed V region heterogeneity; they variably cross-react with 6A PS, an isopolymer of 68 PS. Since even a simple PS molecule expresses multiple epitopes [31] , these antibody clones with differing V regions likely recognize different epitopes with different avidities.
What determines which particular antibody clone against PS will dominate within a given person? Animal studies showed tective, an assumption that is made in fonnulating S. pneumoniae vaccines.
